[{"orgOrder":0,"company":"5 Prime Sciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"5 Prime Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"5 Prime Sciences \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"5 Prime Sciences \/ Eli Lilly"}]

Find Clinical Drug Pipeline Developments & Deals by 5 Prime Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the collaboration, 5 Prime Sciences will utilize its advanced human genetics and AI technologies to identify and validate potential drug targets for cardio-metabolic diseases & diabetes.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 09, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Discovery

                          Sponsor : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank